S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
66,000% upside on tiny biotech? (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
66,000% upside on tiny biotech? (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
66,000% upside on tiny biotech? (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
66,000% upside on tiny biotech? (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage

Allurion Technologies (ALUR) Competitors

$2.85
+0.10 (+3.64%)
(As of 02/23/2024 08:52 PM ET)

ALUR vs. BLUA, BWAY, STIM, KRMD, DCTH, MGRM, TELA, INO, SRTS, and CLPT

Should you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include BlueRiver Acquisition (BLUA), BrainsWay (BWAY), Neuronetics (STIM), KORU Medical Systems (KRMD), Delcath Systems (DCTH), Monogram Orthopaedics (MGRM), TELA Bio (TELA), Inovio Pharmaceuticals (INO), Sensus Healthcare (SRTS), and ClearPoint Neuro (CLPT). These companies are all part of the "surgical & medical instruments" industry.

Allurion Technologies vs.

Allurion Technologies (NYSE:ALUR) and BlueRiver Acquisition (NYSE:BLUA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Allurion Technologies currently has a consensus price target of $5.00, suggesting a potential upside of 75.44%. Given Allurion Technologies' higher probable upside, equities research analysts plainly believe Allurion Technologies is more favorable than BlueRiver Acquisition.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Allurion Technologies
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
BlueRiver Acquisition
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Allurion Technologies has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500. Comparatively, BlueRiver Acquisition has a beta of 0.01, suggesting that its stock price is 99% less volatile than the S&P 500.

In the previous week, Allurion Technologies had 1 more articles in the media than BlueRiver Acquisition. MarketBeat recorded 1 mentions for Allurion Technologies and 0 mentions for BlueRiver Acquisition. Allurion Technologies' average media sentiment score of 1.53 beat BlueRiver Acquisition's score of 0.00 indicating that Allurion Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Allurion Technologies Very Positive
BlueRiver Acquisition Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Allurion TechnologiesN/AN/A$32.37MN/AN/A
BlueRiver AcquisitionN/AN/A$8.49MN/AN/A

26.6% of Allurion Technologies shares are held by institutional investors. Comparatively, 19.7% of BlueRiver Acquisition shares are held by institutional investors. 20.0% of Allurion Technologies shares are held by insiders. Comparatively, 79.0% of BlueRiver Acquisition shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Allurion Technologies' return on equity of 0.00% beat BlueRiver Acquisition's return on equity.

Company Net Margins Return on Equity Return on Assets
Allurion TechnologiesN/A N/A -16.60%
BlueRiver Acquisition N/A -24.55%-1.70%

Allurion Technologies received 1 more outperform votes than BlueRiver Acquisition when rated by MarketBeat users.

CompanyUnderperformOutperform
Allurion TechnologiesOutperform Votes
1
100.00%
Underperform Votes
No Votes
BlueRiver AcquisitionN/AN/A

Summary

Allurion Technologies beats BlueRiver Acquisition on 9 of the 11 factors compared between the two stocks.


Get Allurion Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALUR vs. The Competition

MetricAllurion TechnologiesSurgical & medical instruments IndustryMedical SectorNYSE Exchange
Market Cap$135.40M$3.67B$4.82B$17.39B
Dividend YieldN/A2.20%5.40%3.57%
P/E RatioN/A18.56243.8524.66
Price / SalesN/A25.723,035.448.64
Price / Cash1.9028.1190.7117.56
Price / Book-7.503.904.385.73
Net Income$32.37M$16.44M$108.96M$865.23M
7 Day Performance1.42%-1.85%112.79%0.81%
1 Month Performance-11.76%1.87%121.54%2.53%
1 Year PerformanceN/A-12.63%133.28%5.99%

Allurion Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLUA
BlueRiver Acquisition
0 of 5 stars
$10.75
+0.3%
N/A+6.1%$106.00MN/A0.003
BWAY
BrainsWay
1.5953 of 5 stars
$6.34
+0.3%
$7.00
+10.4%
+212.4%$105.38M$28.79M-25.36134News Coverage
STIM
Neuronetics
2.2724 of 5 stars
$3.28
+2.5%
$9.50
+189.6%
-37.3%$94.90M$69.23M-2.78211
KRMD
KORU Medical Systems
2.7153 of 5 stars
$2.08
+0.5%
$3.63
+74.3%
-47.9%$94.54M$28.68M-12.2485
DCTH
Delcath Systems
3.716 of 5 stars
$4.28
+1.7%
$18.00
+320.6%
-12.0%$94.37M$2.72M-1.2852Gap Up
MGRM
Monogram Orthopaedics
0 of 5 stars
$3.01
-0.7%
N/AN/A$93.70M$630,000.000.0027Upcoming Earnings
Gap Up
TELA
TELA Bio
3.589 of 5 stars
$7.06
+0.9%
$14.67
+107.7%
-35.9%$172.90M$41.42M-3.43173Positive News
INO
Inovio Pharmaceuticals
4.0942 of 5 stars
$7.66
-2.9%
$13.33
+74.1%
-48.7%$174.19M$10.26M-1.01184
SRTS
Sensus Healthcare
2.7038 of 5 stars
$4.73
+1.3%
$7.50
+58.6%
-28.8%$77.49M$24.41M157.7242
CLPT
ClearPoint Neuro
0.8566 of 5 stars
$7.49
+4.2%
$11.50
+53.5%
-10.0%$184.40M$20.55M-8.32108

Related Companies and Tools

This page (NYSE:ALUR) was last updated on 2/26/2024 by MarketBeat.com Staff